Cizzle Biotechnology, developer of a blood test for early-stage lung cancer, ranked among the UK market's most volatile shares on 23 September 2026. Its test is now available to US physicians, but the company is tiny, pre-revenue on a reported basis and funded partly through convertible Loan notes.
Cizzle Biotechnology (LSE:CIZ) is a UK diagnostics developer whose lead product is a blood test for the CIZ1B biomarker, which the company says is highly associated with early-stage lung cancer. Its shares were among the most volatile on the UK market on 23 September 2026.
Unlike many small UK biotech companies, Cizzle is not on AIM. It was admitted to the Official List and Main Market of the London Stock Exchange in May 2021, and its shares sit in the transition listing category for former standard-listed companies. No FTSE index membership is shown on its exchange page. With a Market Value below £7m, company announcements about US commercial roll-out can move the share price sharply.
Why Cizzle Biotechnology (CIZ) Is in Focus
2026 has been Cizzle's most eventful year since listing. In June, its CIZ1B test was approved for clinical use in a US laboratory; in July, its North American licensee began selling the test in Texas; and in August, a second laboratory agreement was signed.
On 23 September 2026 the shares stood at 1.65p, with a 52-week range of 1.20p to 3.90p and a Market Capitalisation of about £6.8m. The shares showed a six-month fall of about 27% but a five-day gain of about 10%, illustrating how quickly the price can change direction.
What Does Cizzle Biotechnology Do?
CIZ1B is a naturally occurring variant of the CIZ1 nuclear protein and can be measured in small quantities of blood. Cizzle has developed it into a non-invasive test intended to help detect lung cancer early. The company describes its model as low-cost: it licenses the technology to partners in return for royalties, rather than building its own sales force or laboratories.
In North America, the licensee is Cizzle Bio Inc (BIO). Cizzle says aggregate minimum Royalty receipts committed under that agreement have increased to about US$5.9m. It also has a licensing arrangement covering the Caribbean and a scientific collaboration with the Moffitt Cancer Center in Florida.
What Has Been Happening Recently?
On 4 February 2026 the company announced a Patent grant in Canada, followed by a US patent grant on 12 June covering its core methods for measuring CIZ1B. On 16 June it announced that the test had been approved for clinical use under the US Clinical Laboratory Improvement Amendments (CLIA) at OmniHealth Diagnostics in Dallas, Texas.
On 22 July, Cizzle said BIO had made the test available to licensed healthcare providers in the Dallas-Fort Worth and San Antonio areas. On 3 August it reported a second laboratory agreement, with San Antonio-based BioBridge Global, whose Subsidiary has begun the independent validation needed before it can offer the test. Because CIZ1B is a laboratory-developed test, each laboratory must validate it separately.
Zeus became corporate broker on 30 June 2026.
What Are the Numbers Saying?
Hard financial figures are limited. Cizzle has not yet published its 2026 half-year results, and its 15 July operational update gave no Revenue or cash figures. The company reported no revenue for 2025 and a net loss of about £691,000.
Funding has come largely from one existing investor, Frazer Lang. Convertible loan notes of £150,000 issued in May 2025 and £250,000 issued in November 2025 were converted on 6 May 2026 into 28,571,429 new shares at 1.4p each. A further Facility of up to £250,000, announced on 2 April 2026, is convertible at 1.4p until 30 October 2026, and the company had drawn £100,000 of it by 6 May.
Why Is the Share Price Attracting Attention?
The facts are that the share price has swung between 1.20p and 3.90p over the past year, and that the company has issued a string of regulatory milestones about its US launch.
One possible interpretation is that investors are trying to price a binary question: whether US physicians will order the test in meaningful volumes, which would feed through to royalties. Some investors may view CLIA approval and the first sales as reducing risk, as the board argues; others may wait for evidence of test volumes or royalty income.
Several structural factors can amplify moves. The shares trade in fractions of a penny on SETSqx, a quote-driven service, so small absolute moves become large percentage changes. The convertible notes carry a conversion price of 1.4p, not far below the current price, so further conversions could add shares to the market.
How Does the London Stock Exchange Main Market Context Matter?
As a Main Market company, Cizzle is subject to FCA transparency rules, including a requirement to publish half-year reports within three months of the period end. Cizzle's 2025 interim results were published on 30 September 2025.
However, its listing category and size mean it is not shown as a member of a FTSE index, so movements in the FTSE All-Share or FTSE 100 have little direct bearing on it. There is no evidence that broader market moves caused its recent volatility; its own announcements are the more likely drivers.
What Could Investors Watch Next?
Factual items to monitor include:
- Half-year results: due by the end of September 2026, which should give cash and loss figures for the first half.
- US laboratory roll-out: completion of validation at BioBridge Global and further CLIA laboratory partners, as BIO has targeted sites in several US states.
- Royalty evidence: any disclosure of test volumes or royalty receipts from North America.
- Funding: use or conversion of the remaining convertible facility before its 30 October 2026 conversion deadline, and any new financing.
- New territories: the board has said it is negotiating royalty-bearing agreements in the UK, Europe and Asia-Pacific.
The Bottom Line
Cizzle Biotechnology (LSE:CIZ) stands out among volatile UK stocks because it combines a sub-£7m market value, a penny share price and news with potentially large consequences. In 2026 the company has secured US and Canadian patents, CLIA approval for its CIZ1B lung cancer blood test, a Texas commercial launch through its licensee and a second laboratory agreement. Against that, financial disclosure is thin and funding depends on convertible notes. The next half-year report and any evidence of US test volumes or royalties are likely to matter most.






Please wait processing your request...